New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTBAYRY, ONXXBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Check below for free stories on BAYRY;ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
September 16, 2014
07:31 EDTBAYRYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 8, 2014
07:15 EDTBAYRYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
07:22 EDTBAYRYBayer unit aims to invest $1B before FY16 in U.S., Reuters says
Subscribe for More Information
05:37 EDTBAYRYRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use